The Market Herald - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Digital health company 1st Group (1ST) has received commitments to raise $4.5 million through a placement
  • The funds will be used to support 1st Group’s growth strategy including additional sales and marketing capabilities and technology development
  • The placement shares will be issued on or around December 18.
  • 1st group is up 5.48 per cent following news of the placement and shares are trading for 7.7 cents each

Digital health company 1st Group (1ST) has received commitments from institutional, sophisticated and professional investors for a $4.5 million placement.

The placement will issue 69,230,769 fully paid ordinary shares at an issue price of $0.065 per share; an 11 per cent discount to the last price before the trading halt.

Funds raised under the placement will be used to support 1st Group’s growth strategy including additional sales and marketing capabilities, technology development, working capital requirement and other general corporate purposes.

“We are delighted with the strong support shown by existing and new investors for 1st Group. This raise was initiated by institutional investor interest and reflects the confidence in our growth strategy and market opportunities,” CEO Klaus Bartosch said.

1st Group is a digital health company with integrated platforms that provide an easy way for health professionals and patients to book and schedule appointments.

The placement shares will be issued on or around December 18.

1st group is up 5.48 per cent following news of the placement and shares are trading for 7.7 cents each at 1:44 pm AEDT.

1ST by the numbers
More From The Market Herald

The Calmer Co locks in $700k in funding via convertible note issue

The Calmer Co (ASX:CCO) has confirmed its receipt of $700,000 in funding from existing shareholders.

FDA greenlights Botanix Pharmaceuticals’ Sofdra resubmission plan

FDA approves Botanix's strategy for Sofdra NDA resubmission with no additional materials requested, keeping submission to…

Botanix Pharmaceuticals successfully closes $13.5m Placement to boost US commercial activities

Botanix Pharmaceuticals (ASX: BOT) has closed its $13.5 million placement to both new and existing institutional…

Pharmaust completes Phase One Monepantel study and files for Orphan Drug Designation

Pharmaust (ASX:PAA) has announced that all patients have completed its phase one MEND study using monepantel…